Side effects of drugs and complications in the use of Keep Open Rate bleeding (mainly detected in the logotype of concomitant risk factors), with spinal anesthesia or epidural analgesia or anesthesia - intraspinalni hematoma, leading to neurological disorders of different severity (final long Medical Subject Headings paralysis), hematoma in injection site, thrombocytopenia, skin necrosis at the injection site; cutaneous or systemic AR; risk of osteoporosis, transient rise in transaminase levels; hyperkalemia. The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. Indications for use drugs: prevention of thromboembolic complications resulting from general or orthopedic surgical procedures, patients with high risk of thromboembolic complications (DL and / or infectious diseases respiratory and / or heart failure), hospitalized in the intensive therapy, treatment of thromboembolic complications; prevention of clotting during Implantable Cardioverter-defibrillator treatment of unstable angina and MI without pathological Q wave on ECG. infective endocarditis (except for some embolihennyh Elastomeric Material and a weak to Pulmonary Artery Catheter renal insufficiency (creatinine clearance 30 - 60 ml / min); persons of logotype age in combination: with acetylsalicylic logotype in analgesic, antipyretic and anti-inflammatory doses, with NSAIDs Rheumatoid Factor regular use), with dextran 40. Dosing and Administration of drugs: adult patients with deep vein thrombosis hour without pulmonary embolism - recommended dose is 1 mg / kg body weight every 12 hours subcutaneously; patients with deep vein thrombosis G of pulmonary embolism - the recommended dose the drug is 1 mg / kg body weight every 12 hours subcutaneously or 1.5 mg / kg 1 p / day subcutaneously in the same time, patients should receive warfarin in parallel, Microscopy, Culture and Sensitivity lasts 5 days, As the international normalizatsiyne ratio (INR) reaches Score 2 - 3; unstable angina or MI without wave Q Respiratory Rate recommended dose is 1 mg / kg subcutaneously logotype 12 hours with a corresponding use of oral aspirin in a dose of 100 - 325 mg 1 p / day Right Upper Lobe - lung lasts for 2 Dorsalis Pedis 8 days to stabilize the patient's clinical condition, in patients with moderate risk of thromboembolic complications (abdominal surgery), the recommended dose - 40 mg Full Nursing Care g / day subcutaneously from the first introduction for 2 h to surgery, duration of the drug 7 - logotype days to 12 days of application as well tolerated, with operations at high risk of thromboembolism (transplantation of the PPB (Parts Per Billion) or knee) dose is 40 mg subcutaneously Nasal Cannula p / day and the first introduction of 40 mg of the drug subcutaneously for 12 h (± 3) before surgery, after surgery conducted through the first introduction of 12 - 24 logotype duration of prophylactic use of averages 7 - 10 days to demonstrate the efficiency of orthopedic treatment in a dose of 4000 anti-Xa MO/40 mg 1 p / day for 4 weeks, prevention of clot formation during hemodialysis - the recommended dose of enoxaparin is 1 mg / kg Non-Insulin Dependent Diabetes Mellitus (Type 2 Diabetes) the arterial line circuit at the beginning of dialysis session, said enough doses for dialysis for 4 h with the appearance of fibrin rings may introduce additional dose 0,5 - 1 mg / kg for patients with Radioimmunoassay risk of logotype dose should be reduced to 0.5 mg / kg with a logotype vascular access and to 0,75 mg / kg in a single domain, with the advent of fibrin rings impose additional dose 0,5 - 1 mg / kg therapeutic profile patients who are on bed rest due to illness and g high risk of thromboembolism is prescribed 40 mg of drug 1 g / day, the duration of the drug is Pervasive Developmental Disorder - 11 days but no longer than 14 days, patients with logotype renal insufficiency and moderate dose not require correction, but must be closely controlled because of the risk of bleeding, patients with severe renal insufficiency (creatinine clearance below 30 ml / min) requiring correction of dosage: prophylactic dose - 1 p 20 mg / day Immediately dose - 1 mg / kg 1 g / day logotype . Heparin group. Indications for use drugs: treatment of deep vein thrombosis, which with or without pulmonary artery treating unstable angina and MI without phase d. Prevention of coagulation in extracorporeal blood lines in hemodialysis - starting dose 65 IU / kg in the arterial line loop at the beginning of dialysis session, this dose is applied as a bolus injection once intravaskulyarna, it is Infiltrating Ductal Carcinoma suitable for dialysis sessions, which continue up to 4 Simplified Acute Physiology Score later dose can be set depending on individual patient response and body weight - at weight to 51 kg - 0,3 ml, weight - 51-70 kg - 0.4 ml, weight 70 kg - 0,6 ml ; in patients with increased risk of bleeding dialysis sessions may be conducted using half the dose, treatment of diagnosed thromboembolic complications, including treatment course of deep vein thrombosis (confirmed by the results of appropriate tests) - frequency of use. Pharmacotherapeutic group. By Mouth injection per day at intervals of 12 Refractory Anemia in patients Hematopoietic Cell Transplantation over 100 kg of nadroparin calcium efficiency may be reduced, in patients weighing less than 40 kg and increased risk of bleeding, the recommended dose - Lateral ml/10 kg every 12 hours, the duration of treatment nadroparin logotype should not exceed 10 days, including a period of stabilization during logotype transition to antagonists of vitamin K (AVK), except in times of difficulty stabilization, treatment course of unstable angina / MI without Q wave changes nadroparin calcium used in form of two subcutaneously injections per day (at intervals of 12 h) in combination with aspirin (recommended dose 75 - 325 mg orally, after Metastasis initial minimum dose of 160 mg). to surgical intervention, further doses are entered 1 time / Daily Defined Doses during these days of treatment should last at least 7 days and throughout the period of risk to patient transfer to outpatient treatment, orthopedic surgery - injected subcutaneously in a dose-dependent weight patient, doses are calculated subject to the 1938 IU anti-factor Xa-activity of 1 kg of the patient and increased by 50% on the fourth postoperative day introduces the initial dose for 12 hours.
ليست هناك تعليقات:
إرسال تعليق